The Journal of Immunology, Vol 150, Issue 11 5154-5162, Copyright © 1993 by American Association of Immunologists

ARTICLES

EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2

R Khanna, SR Burrows, A Suhrbier, CA Jacob, H Griffin, IS Misko, TB Sculley, M Rowe, AB Rickinson and DJ Moss
Queensland Institute of Medical Research, Bancroft Centre, Brisbane, Australia.

The pathogenesis of EBV+ Burkitt's lymphoma (BL) suggests evasion of the CTL response against EBV. Two important features of this tumor have been previously suggested to explain this immune evasion, (a) absence/low expression of cellular adhesion molecules and (b) restricted expression of EBV latent Ag. To determine the relative importance of these features in relation to evasion of EBV-specific CTL, a group of BL cell lines with variable expression of the aforementioned phenotypic characteristics were assayed for specific CTL lysis after exogenous addition of EBV peptide epitopes. In spite of down-regulated expression of the adhesion molecules LFA-1, LFA-3, and/or ICAM-1, peptide-sensitized BL cells were recognized and lysed by EBV-specific CTL. Moreover, there was no significant difference between the CTL lysis of the BL cells and that of adhesion molecule-positive control cells over a wide range of peptide epitope concentrations. Blocking experiments with mAb to individual adhesion molecules suggested that virus-specific CTL recognition of lymphoblastoid cell lines was dependent on an intact LFA-3/CD2 pathway. In contrast, the CTL recognition of peptide-sensitized BL cells was critically dependent on the LFA-1/ICAM pathway, with an insignificant contribution by CD2/LFA-3. The consistently high expression of ICAM-2 on all BL cell lines suggests that the accessory function in CTL recognition of these cells is mediated by the LFA-1/ICAM-2 pathway. Thus, down-regulation of LFA-1, LFA-3, and/or ICAM-1 expression on BL cells does not provide an absolute barrier to tumor cell recognition by virus-specific CTL. The ability of virus-specific CTL to recognize peptide epitope-sensitized BL cells as efficiently as normal cells has demonstrated the importance of latent Ag expression in the CTL control of EBV+ tumors.

This article has been cited by other articles:

				J. Tellam, C. Smith, M. Rist, N. Webb, L. Cooper, T. Vuocolo, G. Connolly, D. C. Tscharke, M. P. Devoy, and R. Khanna From the Cover: Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition PNAS, July 8, 2008; 105(27): 9319 - 9324. [Abstract] [Full Text] [PDF]

				S. L. Elliott, A. Suhrbier, J. J. Miles, G. Lawrence, S. J. Pye, T. T. Le, A. Rosenstengel, T. Nguyen, A. Allworth, S. R. Burrows, et al. Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis J. Virol., February 1, 2008; 82(3): 1448 - 1457. [Abstract] [Full Text] [PDF]

				M. S. Staege, S. P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A. B. Rickinson, M. G. Masucci, A. Polack, and G. W. Bornkamm MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells PNAS, April 2, 2002; 99(7): 4550 - 4555. [Abstract] [Full Text] [PDF]

				S. A. Thomson, S. R. Burrows, I. S. Misko, D. J. Moss, B. E. H. Coupar, and R. Khanna Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design J. Virol., March 1, 1998; 72(3): 2246 - 2252. [Abstract] [Full Text] [PDF]

				A. P. Sing, R. F. Ambinder, D. J. Hong, M. Jensen, W. Batten, E. Petersdorf, and P. D. Greenberg Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV+ Hodgkin's Disease Blood, March 15, 1997; 89(6): 1978 - 1986. [Abstract] [Full Text] [PDF]

				M. S. Staege, S. P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A. B. Rickinson, M. G. Masucci, A. Polack, and G. W. Bornkamm MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells PNAS, April 2, 2002; 99(7): 4550 - 4555. [Abstract] [Full Text] [PDF]